Student Dissertation

Agency : Competitive Landscape; Forecasting; Decision Making; Systematic Review; Pipeline Molecules

Objective : The research question developed was to identify the disease overview and current market dynamics for primary & metastatic liver cancer, bladder cancer and acute lymphocytic leukaemia in the U.S. Accordingly, the research objectives were developed: To create Therapy Area Overview (TAO) of primary & metastatic liver cancer, bladder cancer and acute lymphocytic leukemia which includes their clinical overview, epidemiology and disease management To study the market dynamics of these cancers in the U.S

Background : Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer. It has remained the interest area for various pharmaceutical companies as cancer is the second leading cause of deaths in the U.S and some of the common cancers include bladder cancer, primary and metastatic liver cancer, leukemia, breast cancer, lung cancer etc. In recent decades, tremendous progress has been made in the fight against cancer. Advances in molecular and genomic research have revealed underlying complexities and provided insights into cancer. Currently, more than 800 medicines and vaccines are in clinical testing for cancer. Despite these advancements, huge unmet need still exists in this therapy area making it an attractive market for the pharmaceutical companies. Big companies are launching new drugs with better efficacy and many small players are also entering the market. Therapy Area Overview (TAO) provides the comprehensive overview of a disease, its etiopathogenesis, treatment and market dynamics. This information is used in internal decision making to help the organization identify its prospective clients. TAO also aids in forecasting for a disease by assessing the opportunity areas and competitive landscape for that disease. It could also be leveraged to provide business solutions to various pharmaceutical companies thereby helping them plan the launch of their drugs in the market.

Methodology : The methodology included systematic review and secondary desk research for primary & metastatic liver cancer, bladder cancer & acute lymphocytic leukaemia based on the following parameters: clinical overview, diagnosis, treatment, epidemiology and market dynamics. Data sources used were various research papers and articles on primary & metastatic liver cancer, bladder cancer and leukaemia and publically available secondary research data source like Medscape, Epocrates, WebMD, SEER (Surveillance, Epidemiology and End Result), American Cancer Society, NCCN guidelines (National Comprehensive Cancer Network), obroncology; ZS specific data sources. Data for market dynamics was analyzed using pivot tables and charts.

Findings : Following the reviews, clinical overview of the cancers was described; flowcharts were used to explain the treatment flow; graphs and tables were used to describe the epidemiological pattern and market dynamics of the disease. Then these parameters were correlated to draw the inferences and to assess the various opportunity areas available for future developments. It was seen that the market for primary and secondary liver cancer is still at nascent stage where not many competitors are present; but the pipeline for them is buzzing with many molecules. Market for bladder cancer is expected to expand vastly in the near future. Market for ALL is huge with many big and small players competing for the market share.

Recommendations : TAO has many important business implications which include its use in onboarding process; repository; assess opportunity area and plan new drug launch. Various specific implications of TAO include Clinical overview & Disease management used for onboarding process and to know the evolution in treatment modalities; Epidemiology which helps to assess target population, unmet needs and trends in epidemiological patterns; Market dynamics which details about recent developments, competitive landscape and plan the launch using information regarding patent expiry & first launch.


x